Dr Philippe Guillet has joined the French drug discovery company ExonHit Therapeutics as vice president of clinical research. He will be responsible for the clinical studies of ExonHit Therapeutics' Ready for Development Compounds (RDCs). The company has also appointed Frederique Schlumberger as general counsel.
Ms Schlumberger, an international corporate and commercial lawyer, will be responsible for managing ExonHit Therapeutics' global intellectual property portfolio. And Christina Hedberg has been appointed as senior director, business development, working out of the company's US subsidiary in Gaithersburg, MA.
Dr Philip Wright has been appointed director of science and technology at the Association of the British Pharmaceutical Industry (ABPI). Dr Wright's career includes roles at the CBI, Glaxo Wellcome and the Centre for Exploitation of Science and Technology. He succeeds Dr Jeff Kipling, who has left the ABPI.
Astex Technology, the UK structure-based drug discovery company, has appointed Peter Fellner as non-executive chairman of the board. Dr Fellner, currently ceo of the Celltech Group, previously served as ceo of Roche UK for four years from 1986 to 1990.
Lindon Roberts has joined the specialist process engineering contractor RB Plant Construction as business development manager after two years at Powder Systems. Lindon is qualified in both business studies and engineering and is closely associated with the ISPE (International Society for Pharmaceutical Engineers) at both Affiliate and Regional levels.
Dutch life sciences company Screentec, based in Leiden, has named Dr Gerard Dijkstra as ceo. He is a former head of biotechnology at Solvay Pharmaceuticals and brings more than 12 years experience in drug discovery to Screentec.
Oxford GlycoSciences has announced the appointment of David Ebsworth to the position of ceo, with effect from 1 July. Dr Ebsworth has more than 20 years' experience within the pharmaceutical industry, and was most recently head of the worldwide pharmaceutical business group of Bayer AG.
He replaces Dr Kranda, who helped build OGS into a £320m (Euro 494m) company focused on proteomics and genomics.